Screening for neuroblastoma in North America : Preliminary results of a pathology review from the Quebec project.
The Quebec Neuroblastoma Screening Project was initiated to assess clinical and biologic aspects of neuroblastomas detected by screening infants born in the province of Quebec from May 1,1989, to April 30,1994.
Infants were screened for preclinical detection of neuroblastoma by determination of catecholamine metabolites, vanillylmandelic acid (VMA), and homovanillic acid (HVA).
Patients with tumors discovered through this screening as well as patients in the same birth cohort with clinically detected tumors were referred to Quebec Oncology Centers for further investigation, diagnosis, and treatment.
Pathology specimens were submitted to Childrens Hospital Los Angeles for central review.
Tumors were histopathologically classified according to the Shimada system.
As of August, 1993,340,000 infants were screened at 3 weeks and 245,000 of them were retested at 6 months of age.
Thirty-one tumors were detected through this screening and removed.
Histologic material was available for 27 cases
14 were detected at 3 weeks of age and 13 at 6 months of age.
Twenty-six patients had tumors with favorable histology (FH), and one patient had a Stage I tumor with unfavorable histology (UH).
At the time of this writing, all mass screening patients are alive, including one child with relapsed disease.
During this period, 48 tumors were detected clinically in the same birth cohort, 40 of which were evaluated histologically.
Of these 40 cases, ...
Mots-clés Pascal : Neuroblastome, Nouveau né, Homme, Nourrisson, Programme sanitaire, Dépistage, Histopathologie, Pronostic, Québec, Canada, Amérique du Nord, Amérique, Stade précoce, Système nerveux pathologie, Système nerveux sympathique pathologie, Tumeur maligne
Mots-clés Pascal anglais : Neuroblastoma, Newborn, Human, Infant, Sanitary program, Medical screening, Histopathology, Prognosis, Quebec, Canada, North America, America, Early stage, Nervous system diseases, Autonomic neuropathy, Malignant tumor
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0236809
Code Inist : 002B17E. Création : 199608.